Verona Pharma - RNS (29th September 2015)

Verona Pharma (VRP) - Update on RPL554 Clinical Study

The RNS released this morning looks encouraging, see below:

---------------------------------  Start of RNS Summary  ---------------------------------------------------------------------------------------------

29 Sep 2015 07:00:00

Verona Pharma PLC

Verona Pharma plc

("Verona Pharma" or the "Company")

 Positive headline data from RPL554 clinical study in COPD patients

New suspension formulation is well tolerated; results signal marked improvement in lung function 

RPL554 remains on track for entry into Phase IIb clinical trials in 2H 2016

29 September 2015, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces encouraging positive headline data of the third and final part (part C) of a randomised, double blind, placebo controlled Single Ascending Dose (SAD) / Multiple Ascending Dose (MAD) clinical study in stable chronic obstructive pulmonary disease (COPD) patients. This study uses a new proprietary and commercially scalable nebulised suspension formulation of the Company?s lead pipeline drug, RPL554.^1,2 The primary objective of this part of the study was to show the safety and tolerability of the new drug formulation in stable COPD patients with moderate severity of disease.³ Measurement of lung function using FEV1⁴ was included. Evaluation of the full data set is ongoing and will be presented in an appropriate scientific, peer-reviewed forum at a later date.

Highlights: Part C of study in 32 stable COPD patients with moderate disease severity³

• Primary objective of study met: Drug formulation well tolerated at all dose levels; No serious adverse events reported
  • Adverse event profile similar to that seen with placebo
  • Absence of gastro-intestinal or cardiovascular adverse events

• RPL554 caused pronounced improvement in lung function
  • Mean peak FEV1 increase ranged from 199ml to 257ml versus placebo
  • Extent of bronchodilation exceeds that seen in earlier studies with original proof of concept formulation

• Data continue to support twice daily dosing regimen with RPL554

• Data consistent with that from earlier part A and B of study in healthy volunteers
• Evaluation of the full data set from this trial is ongoing

-------------------------------------------  End of RNS Summary  ----------------------------------------------------------------------------------

The Full announcement can be seen HERE!

The Sharescope price graph is also very interesting...

Verona Pharma - SharePrice Graph (10 months)

Summary

The news-flow has been positive for Verona Pharma, in relation to RPL554 and it could eventually cause this share to "take off". As ever, it's a matter of judgement as to whether to invest (and when)... take a look and let me know what you think.

Mick (29th September 2015)

AGA - Possible Offer (17th June 2015)

Aga Rangemaster Group (AGA) - Possible Offer

Those of us following AGA Rangemaster will be interested in the RNS announcement today, as follows:
-------------------------------------------------------------------------------------------------------------------

RNS Number : 4628Q

Aga Rangemaster Group PLC

17 June 2015

Strictly Private & Confidential

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE

FOR IMMEDIATE RELEASE

17 June 2015

AGA Rangemaster Group plc ("AGA" or the "Company")

Statement regarding Possible Offer

The Company notes the recent movement in the Company's share price and confirms that it is in discussions with The Middleby Corporation ("Middleby") regarding a possible cash offer for the Company.

There can be no certainty that any formal offer will be made, or as to the terms of any offer.

In accordance with Rule 2.6(a) of the Code, Middleby is required, by no later than 5.00 p.m. on 15 July 2015, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make such an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline may be extended with the consent of the Takeover Panel in accordance with Rule 2.6 of the Code.

In accordance with Rule 2.10 of the Code, the Company confirms that, as at the date of this announcement, it has 69,264,223 ordinary shares of 46 7/8p nominal value each in issue and admitted to trading on the London Stock Exchange's main market for listed securities. The International Securities Identification Number of the ordinary shares is GB00B2QMX606. 

In accordance with Rule 26.1 of the Code, a copy of this announcement will be available on the Company's website at www.agarangemaster.com. 

The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.

-------------------------------------------------------------------------------------------------------------------

The affect on the share price was a gain of 31.25p (+30.0%) today, as can be seen from the graph below...